Detalhe da pesquisa
1.
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10382): 1079-1090, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868261
2.
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 399(10328): 945-955, 2022 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219377
3.
Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Allergol Int
; 72(3): 451-457, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858856
4.
Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
Ann Allergy Asthma Immunol
; 125(3): 334-340.e1, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445670
5.
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
Blood
; 127(14): 1761-9, 2016 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755710
6.
Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
Allergy Asthma Proc
; 39(5): 365-370, 2018 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30107868
7.
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
Blood
; 120(12): 2405-11, 2012 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22859609
8.
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Lancet Haematol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710185
9.
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
J Allergy Clin Immunol Pract
; 7(6): 1793-1802.e2, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30772477
10.
Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
Thromb Haemost
; 116(4): 659-68, 2016 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27583313
11.
Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration.
Neuropharmacology
; 43(5): 847-56, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12384170
12.
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.
J Allergy Clin Immunol Pract
; 7(6): 2035-2038, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30660873